---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-023846"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:41:51.418655+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BiomX reports Q4 2022 net loss $28.3M; BX004 Part 1 shows >90% bacterial reduction

## Summary
- Cash, short-term deposits, restricted cash $34.3M at Dec 31, 2022; cash runway through at least mid-2024.
- Net loss for 2022 was $28.3M vs $36.2M in 2021; R&D expenses $16.2M, down from $22.7M.
- BX004 Phase 1b/2a Part 1: mean P. aeruginosa reduction of 1.42 log10 CFU/g vs placebo 0.28; no safety events.
- Part 2 dosing initiated; results expected Q3 2023; CF Foundation to invest $2M second tranche.
- Raised $7.5M private placement in Feb 2023; $6M contingent on shareholder approval; OrbiMed and CF Foundation participated.

## SEC filing metadata
- accession: 0001213900-23-023846
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.08, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/0001213900-23-023846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/ea175977-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-023846
- JSON: https://secwatch.observer/filing/0001213900-23-023846.json
- Plain text: https://secwatch.observer/filing/0001213900-23-023846.txt

## Key facts
- Earnings Releases
  BiomX Inc. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 29, 2023, BiomX Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/0001213900-23-023846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.